• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biocorrx Inc (OP:BICX)

0.4000 UNCHANGED
Last Price Updated: 2:23 PM EST, Jan 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 100
Open 0.4000
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.4000
Today's Range 0.4000 - 0.4000
52wk Range 0.2044 - 0.5575
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
BioCorRx, Inc. Announces Initiation of Clinical Study by Majority-Owned Subsidiary BioCorRx Pharmaceuticals, Inc. Evaluating Long-Acting Naltrexone Implant With or Without Bupropion
January 14, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BioCorRx Announces Appointment of Louis Lucido as Board Chair
January 06, 2026
Via TheNewswire.com

Performance

YTD
+36.1%
+36.1%
1 Month
+0.0%
+0.0%
3 Month
N/A
N/A
6 Month
-7.0%
-7.0%
1 Year
-23.8%
-23.8%

More News

Read More
News headline image
BioCorRx Announces Appointment of Louis Lucido as Board Chair
January 06, 2026
Via NewMediaWire
News headline image
BioCorRx Provides Update on OTC Markets Quotation Status and Planned Form S1 Filing
December 24, 2025
Via NewMediaWire
Topics Regulatory Compliance
BioCorRx Provides Update on OTC Markets Quotation Status and Planned Form S1 Filing
December 24, 2025
Via TheNewswire.com
Topics Regulatory Compliance
BioCorRx, Inc. Announces Q3 2025 Results: Second Straight Quarter of Meaningful Revenue Driven by LUCEMYRA(R) Acquisition
November 18, 2025
Via TheNewswire.com
BioCorRx Reports Business Update for the First Quarter of 2025
May 20, 2025
Via TheNewswire.com
Topics Death
News headline image
BioCorRx Inc. to Present at the Life Sciences Virtual Investor Forum December 11th
December 10, 2025
From Virtual Investor Conferences; BioCorRx Inc.
Via GlobeNewswire
News headline image
Life Sciences Virtual Investor Forum Agenda Announced for December 11th
December 09, 2025
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
BioCorRx, Inc. Announces Q3 2025 Results: Second Straight Quarter of Meaningful Revenue Driven by LUCEMYRA(R) Acquisition
November 18, 2025
Via NewMediaWire
News headline image
BioCorRx Reports 3,985% Revenue Growth to $313K in the First Half of 2025 Driven by LUCEMYRA(R) (lofexidine) Sales
August 14, 2025
Via NewMediaWire
Topics Death
BioCorRx Reports 3,985% Revenue Growth to $313K in the First Half of 2025 Driven by LUCEMYRA(R) (lofexidine) Sales
August 14, 2025
Via TheNewswire.com
Topics Death
News headline image
BioCorRx Reports Business Update for the First Quarter of 2025
May 20, 2025
Via NewMediaWire
Topics Death
News headline image
BioCorRx Pharmaceuticals Inc. Announces That it has Acquired LUCEMYRA(R) (lofexidine), an FDA-Approved Opioid Withdrawal Medication, From USWM, LLC
March 10, 2025
Via NewMediaWire
BioCorRx Pharmaceuticals Inc. Announces That it has Acquired LUCEMYRA(R) (lofexidine), an FDA-Approved Opioid Withdrawal Medication, From USWM, LLC
March 10, 2025
Via TheNewswire.com
News headline image
BioCorRx Reports Business Update for the Second Quarter of 2024
August 15, 2024
Via NewMediaWire
Topics Intellectual Property
News headline image
BioCorRx Reports Business Update for the First Quarter of 2024
May 16, 2024
Via NewMediaWire
Topics Death Intellectual Property
BioCorRx Reports Business Update for the First Quarter of 2024
May 16, 2024
Via TheNewswire.com
Topics Death Intellectual Property
News headline image
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
April 03, 2024
Via NewMediaWire
Topics Intellectual Property
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
April 03, 2024
Via TheNewswire.com
Topics Intellectual Property
News headline image
BioCorRx Reports Business Update for 2023
April 02, 2024
Via NewMediaWire
Topics Death
BioCorRx Reports Business Update for 2023
April 02, 2024
Via TheNewswire.com
Topics Death
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
February 28, 2024
Via NewMediaWire
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
February 28, 2024
Via TheNewswire.com
Topics Death
News headline image
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
February 08, 2024
Via NewMediaWire

Frequently Asked Questions

Is Biocorrx Inc publicly traded?
Yes, Biocorrx Inc is publicly traded.
What exchange does Biocorrx Inc trade on?
Biocorrx Inc trades on the OTC Traded
What is the ticker symbol for Biocorrx Inc?
The ticker symbol for Biocorrx Inc is BICX on the OTC Traded
What is the current price of Biocorrx Inc?
The current price of Biocorrx Inc is 0.4000
When was Biocorrx Inc last traded?
The last trade of Biocorrx Inc was at 01/16/26 02:23 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap